Allergan buys medical aesthetics specialist Zeltiq for $2.475 billion
February 13, 2017Allergan has made another acquisition deal in expanding its medical aesthetics portfolio by buying Zeltiq Aesthetics for $2.475 billion.
Zeltiq’s CoolSculpting system will immediately add to Allergan’s presence in the $4 billion worth market.
“The acquisition of ZELTIQ is highly complementary and strategic to Allergan. By adding the best-in-class body contouring CoolSculpting System to our best-in-class facial aesthetics, plastic surgery and regenerative medicine offerings we are creating a world-class aesthetics business,” said Brent Saunders, Chairman and CEO of Allergan. “With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices, putting Allergan in a unique position to provide expanded customer service, and help meet the needs of patients.”
“Allergan’s world-class medical aesthetics products, global footprint, history and commitment to developing best-in-class aesthetic treatments makes the Company ideally suited to realize the maximum commercial potential of the ZELTIQ controlled-cooling technology platform,” said Mark Foley, Zeltiq CEO.
